Literature DB >> 29333924

Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma.

Xiao Chen1, Tian Xie1, Jingqin Fang1, Wei Xue1, Houyi Kang1, Haipeng Tong1, Yu Guo1, Bo Zhang2, Sumei Wang3, Yizeng Yang4, Weiguo Zhang1,5.   

Abstract

Glomeruloid vascular proliferation (GVP) is a diagnostic hallmark and links to aggressive behavior, therapy resistance and poor prognosis in glioblastoma (GBM). It lacks clinical approaches to predict and monitor its formation and dynamic change. Yet the mechanism of GVPs also remains largely unknown. Using an in situ GBM xenograft mouse model, combined clinical MRI images of pre-surgery tumor and pathological investigation, we demonstrated that the inhibition of tissue factor (TF) decreased GVPs in Mouse GBM xenograft model. TF shRNA reduced microvascular area and diameter, other than bevacizumab. TF dominantly functions via PAR2/HB-EGF-dependent activation under hypoxia in endothelial cells (ECs), resulting in a reduction of GVPs and cancer cells invasion. TF expression strongly correlated to GVPs and microvascular area (MVA) in GBM specimens from 56 patients, which could be quantitatively evaluated in an advanced MRI images system in 33 GBM patients. This study presented an approach to assess GVPs that could be served as a MRI imaging biomarker in GBM and uncovered a molecular mechanism of GVPs.

Entities:  

Keywords:  Biomarker; Glioblastoma; Glomeruloid Vascular Proliferations; Magnetic Resonance Imaging; Tissue Factor

Mesh:

Substances:

Year:  2018        PMID: 29333924      PMCID: PMC5915017          DOI: 10.1080/15384047.2018.1423924

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  40 in total

1.  Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.

Authors:  Oddbjørn Straume; Pierre O Chappuis; Helga B Salvesen; Ole J Halvorsen; Svein A Haukaas; John R Goffin; Louis R Bégin; William D Foulkes; Lars A Akslen
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  The expression of P2X₇ receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas.

Authors:  Jingqin Fang; Xiao Chen; Shunan Wang; Tian Xie; Xuesong Du; Heng Liu; Sumei Wang; Xue Li; Jinhua Chen; Bo Zhang; Huaping Liang; Yizeng Yang; Weiguo Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-03       Impact factor: 4.742

3.  Hypoxia is important in the biology and aggression of human glial brain tumors.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

4.  A novel concept of glomeruloid body formation in experimental cerebral metastases.

Authors:  Balázs Döme; József Tímár; Sándor Paku
Journal:  J Neuropathol Exp Neurol       Date:  2003-06       Impact factor: 3.685

5.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

6.  Expression of tissue factor correlates with grade of malignancy in human glioma.

Authors:  K Hamada; J Kuratsu; Y Saitoh; H Takeshima; T Nishi; Y Ushio
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

7.  Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients.

Authors:  Tatiana C Carneiro-Lobo; Marina T Lima; Andréa Mariano-Oliveira; Angélica Dutra-Oliveira; Sueli M Oba-Shinjo; Suely K N Marie; Mari C Sogayar; Robson Q Monteiro
Journal:  Oncol Rep       Date:  2013-11-28       Impact factor: 3.906

8.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 10.  Brain neoplasms and coagulation.

Authors:  Nathalie Magnus; Esterina D'Asti; Delphine Garnier; Brian Meehan; Janusz Rak
Journal:  Semin Thromb Hemost       Date:  2013-10-09       Impact factor: 4.180

View more
  3 in total

1.  Effects of BMPER, CXCL10, and HOXA9 on Neovascularization During Early-Growth Stage of Primary High-Grade Glioma and Their Corresponding MRI Biomarkers.

Authors:  Wei Xue; Junfeng Zhang; Haipeng Tong; Tian Xie; Xiao Chen; Bo Zhou; Pengfei Wu; Peng Zhong; Xuesong Du; Yu Guo; Youyuan Yang; Heng Liu; Jingqin Fang; Shunan Wang; Hao Wu; Kai Xu; Weiguo Zhang
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

Review 2.  Chaperone-Mediated Autophagy in Pericytes: A Key Target for the Development of New Treatments against Glioblastoma Progression.

Authors:  María Dolores Salinas; Rut Valdor
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

3.  Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy.

Authors:  António G P Bastos; Bruno Carvalho; Roberto Silva; Dina Leitão; Paulo Linhares; Rui Vaz; Jorge Lima
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.